NCT03355794View on ClinicalTrials.gov

A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2022

Conditions
Diffuse Intrinsic Pontine GliomaMalignant Glioma of BrainHigh Grade GliomaBithalamic High Grade GliomaBrainstem GliomaGlioblastomaAnaplastic Astrocytoma
Interventions
DRUG

ribociclib

Oral capsule or liquid formula

DRUG

Everolimus

Oral tablets or dispersible tablets

Trial Locations (7)

20010

Children's National Medical Center, Washington D.C.

28204

Levine Cancer Institute, Charlotte

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Texas Children's Hospital, Houston

98105

Seattle Children's Hospital, Seattle

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Children's Hospital Medical Center, Cincinnati

OTHER